UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 174 filers reported holding UNIQURE NV in Q1 2023. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,979 | +43.7% | 15,055 | +145.5% | 0.00% | – |
| Q2 2023 | $70,247 | -46.4% | 6,133 | -5.8% | 0.00% | – |
| Q1 2023 | $131,124 | -8.9% | 6,513 | +3.1% | 0.00% | – |
| Q4 2022 | $144,000 | -5.9% | 6,320 | -22.0% | 0.00% | – |
| Q3 2022 | $153,000 | -10.0% | 8,099 | -10.6% | 0.00% | – |
| Q2 2022 | $170,000 | +6.9% | 9,060 | +3.2% | 0.00% | – |
| Q1 2022 | $159,000 | -8.6% | 8,778 | +5.8% | 0.00% | – |
| Q4 2021 | $174,000 | -51.4% | 8,299 | -25.7% | 0.00% | -100.0% |
| Q3 2021 | $358,000 | +2.3% | 11,163 | -1.6% | 0.00% | 0.0% |
| Q2 2021 | $350,000 | -29.3% | 11,350 | -22.7% | 0.00% | 0.0% |
| Q1 2021 | $495,000 | +19.0% | 14,689 | +27.4% | 0.00% | 0.0% |
| Q4 2020 | $416,000 | +2.2% | 11,529 | +4.1% | 0.00% | 0.0% |
| Q3 2020 | $407,000 | +23.7% | 11,071 | +51.9% | 0.00% | 0.0% |
| Q2 2020 | $329,000 | -3.8% | 7,286 | +1.2% | 0.00% | 0.0% |
| Q1 2020 | $342,000 | – | 7,202 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |